Drug intelligence / Profile preview

INT-1868

Development stage: Phase 1
Lead developer: Innatus Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

INT-1868 is an investigational small molecule therapeutic being developed by Innatus Therapeutics for the treatment of atopic dermatitis. In October 2026, Innatus Therapeutics initiated a Phase 1 randomized, double-blind, placebo-controlled clinical trial in China to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of oral INT-1868 in healthy adult volunteers. The specific biological target and mechanism of action of INT-1868 have not been publicly disclosed.

Beyond the preview

Go deeper on INT-1868.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-1868.